Regenerating Initial Carious Lesions in the era of AI driven dentistry

Monday, 9th September 2024 - 11:30 to 13:00

Add to Calendar

Timezone:

CEST (Brussels time)

Duration:

90 minutes

Regenerating Initial Carious Lesions in the era of AI driven dentistry

HP6

Session synopsis:

Treating carious lesions traditionally requires restorative procedures that may compromise healthy tooth structure. Consider a ground-breaking, innovative approach that arrests and reverses incipient carious lesions through Guided Enamel Regeneration. Clinically proven biomimetic peptide technology now offers a revolutionary solution for managing early carious lesions (also referred to as "Watch Areas") by regenerating the enamel. This non-invasive, precise, pain-free, and conservative treatment option with a promising success rate above 90%, enhances both patient experience and clinical efficiency.
AI software facilitates detection of incipient lesions from bitewing radiographs that often go undetected, increasing practitioners’ diagnostic accuracy and providing effective patient communication. Once these lesions are detected in their initial stages, treating them with novel biomimetic peptide technology marks a significant advancement in the dental field, effectively turning back the clock on carious progression.

Speakers:

Dr. Goly Abivardi, DMD

CEO and Co-founder

vVARDIS

Dr. med. dent. Goly Abivardi (DMD), Swiss dentist, innovator, and serial entrepreneur, is the CEO and co-founder of vVARDIS a MedTech company with the first product to regenerate enamel for treating incipient lesions with a medical approach. Her professional journey is shared with her sister, Dr. med. dent. Haley Abivardi (DMD) and reflected in their joint endeavours.

After studying medicine and dentistry at the University of Zürich, she co-ran a public paediatric dental clinic in Switzerland, linked to primary schools. This clinic was dedicated to preventive oral health care, aiding thousands of children, particularly from disadvantaged backgrounds.

In 2003, she co-founded Swiss Smile, the first Dental clinic group (DSO), in Switzerland and the first fear free dental clinic group in Europe.

In parallel, she co-ran a Dental Hygiene School. At this time, Dr Goly Abivardi, together with her sister, came across an innovative biomimetic peptide-based technology, able to treat early caries through enamel regeneration, thereby introducing a conservative rather than a restorative approach. To support the adoption of this technology and empower dental professionals with sub-clinical treatment strategies, she co-founded vVARDIS, a life-sciences Med-Tech company, in 2020.

vVARDIS’ mission is to give everyone access to the next generation of preventive dentistry, improving the oral health and overall health of the global population.

Dr. Haley Abivardi, DMD

CEO and Co-founder

vVARDIS

Dr. Med. Dent. Haley Abivardi (DMD), Swiss dentist, innovator, and serial entrepreneur, is the CEO and co-founder of vVARDIS a MedTech company with the first product to regenerate enamel for treating incipient lesions with a medical approach. Her professional journey is shared with her sister, Dr. med. Dent. Goly Abivardi (DMD)and reflected in their joint endeavours.

Haley studied medicine and dentistry at the University of Zürich and then later, co-led, along with her sister, Goly, a public paediatric dental clinic, linked to primary schools that emphasised preventive care, treating thousands of children from low-income backgrounds.

In 2003, she co-founded Swiss Smile, the first Dental clinic group (DSO), in Switzerland and the first fear free dental clinic group in Europe.

In parallel, she co-ran a Dental Hygiene School. At this time, Dr Haley Abivardi, together with her sister, came across an innovative biomimetic peptide-based technology, able to treat early caries through enamel regeneration, thereby introducing a conservative rather than a restorative approach.

To support the adoption of this technology and empower dental professionals with sub-clinical treatment strategies, she co-founded vVARDIS, a life-sciences Med-Tech company, in 2020.

vVARDIS’ mission is to allow everyone access to the next generation of preventive dentistry, improving the oral health and overall health of the global population.

Learning Outcomes:

By completing this session delegates will gain insight into:

Non-Invasive management of early carious lesions through Guided Enamel Regeneration.
Diagnostic options for early carious lesions.
What is Biomimetic Peptide Technology-the science, overview, and mode of action.
The revolutionary non-invasive approach to arrest incipient lesions in their early stages.
Clinical application and workflow.